Abstract
With aging society, one of the more challenging obstacles in percutaneous coronary interventions (PCI) are calcified coronary lesions (CAC). CAC may impede stent delivery; limit balloon and stent expansion, which result in lower minimal stent area (MSA), cause uneven drug distribution, and even hinder wire advancement [1-4]. Lower MSA and stent under-expansion are associated with adverse outcomes, including stent thrombosis, restenosis, and major adverse cardiac outcomes (MACE) [5,6].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
